{"id":"gefitinib-cisplatin-and-radiotherapy","safety":{"commonSideEffects":[{"rate":"46%","effect":"Diarrhea"},{"rate":"34%","effect":"Nausea"},{"rate":"23%","effect":"Vomiting"},{"rate":"21%","effect":"Rash"},{"rate":"17%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2447941","moleculeType":"Small molecule","molecularWeight":"629.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gefitinib is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the signaling pathway that promotes the growth and survival of cancer cells.","oneSentence":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:34.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT00493025","phase":"PHASE2","title":"Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-04","conditions":"Esophageal Cancer","enrollment":19},{"nctId":"NCT00062270","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2003-05","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00258323","phase":"PHASE2","title":"Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-10","conditions":"Esophageal Cancer","enrollment":80},{"nctId":"NCT00290719","phase":"PHASE1","title":"Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2005-11","conditions":"Esophageal Cancer","enrollment":6},{"nctId":"NCT00020709","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":840},{"nctId":"NCT00033449","phase":"PHASE1","title":"Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-02","conditions":"Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","enrollment":30},{"nctId":"NCT00352105","phase":"PHASE1, PHASE2","title":"Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"David Adelstein","startDate":"2006-04","conditions":"Head and Neck Cancer","enrollment":60},{"nctId":"NCT00169221","phase":"PHASE2","title":"Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2005-09","conditions":"Head and Neck Cancer","enrollment":54},{"nctId":"NCT00681967","phase":"PHASE1","title":"Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-02","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT00185835","phase":"PHASE1","title":"Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck","status":"COMPLETED","sponsor":"Stanford University","startDate":"2002-06","conditions":"Head and Neck Cancer, Carcinoma, Squamous Cell","enrollment":10},{"nctId":"NCT00229723","phase":"PHASE2","title":"IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Neoplasms, Squamous Cell","enrollment":224},{"nctId":"NCT00242749","phase":"PHASE2","title":"IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-12","conditions":"Cancer of Head and Neck","enrollment":47},{"nctId":"NCT00135135","phase":"PHASE2","title":"Therapy for Children With Neuroblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-08","conditions":"Neuroblastoma","enrollment":23},{"nctId":"NCT00239304","phase":"PHASE1, PHASE2","title":"Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Head and Neck Neoplasms","enrollment":40},{"nctId":"NCT00195078","phase":"PHASE1, PHASE2","title":"Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-04","conditions":"Head and Neck Cancer","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Gefitinib, Cisplatin and Radiotherapy","genericName":"Gefitinib, Cisplatin and Radiotherapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}